Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Podcasts|July 10, 2026

A BSL-1 Approach to Predicting Viral Clearance in Biomanufacturing

BioPharm International speaks with David Cetlin, Cygnus Technologies, about MockV®, a non-infectious virus-like particle (VLP) technology designed to streamline viral clearance testing in biopharmaceutical manufacturing. Cetlin explains how the BSL-1 based approach allows companies to perform these assessments in-house, replacing reliance on costly, CRO-run live viral spiking studies with easy-to-use kits. The conversation also covers data comparability to the XMuLV gold standard, regulatory traction, and which internal teams are best positioned to lead adoption.

KEY TAKEAWAYS

  • Learn how MockV's® non-infectious VLP technology allows viral clearance testing to be performed in-house at BSL-1, rather than through live viral studies at CROs.
  • Understand how RVLP kit data compares to the XMuLV gold standard retroviral model, based on published third-party research.
  • Discover the current regulatory landscape for MockV® data, including its use in place of live virus studies for clinical trial application filings.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.